China (Mainland)
Diamondsupplier 
99% up by HPLC Apalutamide ARN509 956104-40-8 CAS NO.956104-40-8
- Min.Order: 25 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T
- Product Details
Keywords
- Apalutamide
- ARN509
- Apalutamide 956104-40-8
Quick Details
- ProName: 99% up by HPLC Apalutamide ARN509 9561...
- CasNo: 956104-40-8
- Molecular Formula: C21H15F4N5O2S
- Appearance: White powder
- Application: API
- DeliveryTime: in 7 days after your payment
- PackAge: 1kg/bag ;5kg/drum
- Port: Shanghai/Beijing/Hangzhou
- ProductionCapacity: 50 Metric Ton/Month
- Purity: 99% up
- Storage: Dry place
- Transportation: cool&dry
- LimitNum: 25 Kilogram
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial since 1987.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Details
|
Product name |
Apalutamide / ARN-509 |
|
CAS No. |
956104-40-8 |
|
Molecular Formula |
C21H15F4N5O2S |
|
Molecular Weight |
477.442 |
|
Quality Standard |
99% up by HPLC |
|
Appearance |
White powder |
|
|
|
ITEMS |
SPECIFICATION |
RESULT |
|
Appearance |
White powder |
Conforms |
|
Solubility |
Soluble in water or 1% acetic acid at a concentration of ≥1mg/ml to give a clear, colorless solution |
Conforms |
|
Related Substance (by HPLC) |
Total Impurities ≤ 1.0% |
0.17% |
|
Single impurity ≤ 0.2% |
0.02% |
|
|
Loss on drying |
≤ 0.5% |
0.3% |
|
Assay (by HPLC) |
99.0～103.0% |
99.8%% |
|
Conclusion |
It meets the enterprise standard. |
|
|
|
Function of apalutamide
As a second-generation nonsteroidal androgen receptor inhibitory drug, apalutamide can prevent the fusion of androgen and receptors, and block the transfer of AR to the nucleus of cancer cells. In addition, apalutamide can also control androgen and promote the growth of cancer cells.
The safety and efficacy of apalutamide are based on a randomized clinical trial of 1,207 patients with non-metastatic, castration-resistant prostate cancer. Patients in the trial received apalutamide or placebo. All patients also received hormone therapy, either with a gonadotropin-releasing hormone (GnRH) analog, or with surgery to lower the amount of testosterone in the body (surgical castration). Median metastasis-free survival was 40.5 months for patients taking apalutamide, compared with 16.2 months for patients taking placebo. From the above experiments, we can see that the effect of apalutamide in the treatment of prostate cancer is very significant.
